1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Market For Sanofi And Regeneron’s Zaltrap Could Be Limited

 
• By Martin Berman-Gorvine

Zaltrap gains FDA approval in metastatic colorectal cancer but must compete against several strongly entrenched treatments – Avastin, Vectibix and Erbitux.

Sanofi-Aventis US LLC plans to make its newly approved metastatic colorectal cancer treatment Zaltrap (ziv-aflibercept) available “as soon as possible in the coming weeks,” but with poor expectations for the angiogenesis inhibitor, it may take a long time for the company and partner Regeneron Pharmaceuticals Inc. to see real benefit to their bottom line.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

How Tumult At US FDA Could Impact Merger and Acquisition Strategy

 
• By Joseph Haas and Nielsen Hobbs

With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.

US FDA Not Industry’s ‘Sock Puppet,’ Ultragenyx’s Emil Kakkis Says

 
• By Sue Sutter

The biotech CEO said the Trump Administration’s treatment of FDA employees, including the HHS secretary’s comments about industry capture, are insulting to agency staff, but he is encouraged by FDA Commissioner Martin Makary’s talk of a new conditional approval pathway.

US FDA Asks Adcomm If Opioid Postmarketing Studies Are Relevant, Warrant Action

 
• By Sue Sutter

Two US FDA advisory committees will discuss results from epidemiological studies that attempted to quantify the prevalence, incidence and risk factors for misuse, abuse, overdose and death with opioid analgesics.